These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2042 related articles for article (PubMed ID: 26556876)

  • 21. Alectinib (CH5424802) antagonizes ABCB1- and ABCG2-mediated multidrug resistance in vitro, in vivo and ex vivo.
    Yang K; Chen Y; To KK; Wang F; Li D; Chen L; Fu L
    Exp Mol Med; 2017 Mar; 49(3):e303. PubMed ID: 28303028
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Trametinib modulates cancer multidrug resistance by targeting ABCB1 transporter.
    Qiu JG; Zhang YJ; Li Y; Zhao JM; Zhang WJ; Jiang QW; Mei XL; Xue YQ; Qin WM; Yang Y; Zheng DW; Chen Y; Wei MN; Shi Z
    Oncotarget; 2015 Jun; 6(17):15494-509. PubMed ID: 25915534
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Human ABCB1 (P-glycoprotein) and ABCG2 mediate resistance to BI 2536, a potent and selective inhibitor of Polo-like kinase 1.
    Wu CP; Hsiao SH; Sim HM; Luo SY; Tuo WC; Cheng HW; Li YQ; Huang YH; Ambudkar SV
    Biochem Pharmacol; 2013 Oct; 86(7):904-13. PubMed ID: 23962445
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dinaciclib, a cyclin-dependent kinase inhibitor, is a substrate of human ABCB1 and ABCG2 and an inhibitor of human ABCC1 in vitro.
    Cihalova D; Ceckova M; Kucera R; Klimes J; Staud F
    Biochem Pharmacol; 2015 Dec; 98(3):465-72. PubMed ID: 26300056
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Afatinib circumvents multidrug resistance via dually inhibiting ATP binding cassette subfamily G member 2 in vitro and in vivo.
    Wang XK; To KK; Huang LY; Xu JH; Yang K; Wang F; Huang ZC; Ye S; Fu LW
    Oncotarget; 2014 Dec; 5(23):11971-85. PubMed ID: 25436978
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Elacridar enhances the cytotoxic effects of sunitinib and prevents multidrug resistance in renal carcinoma cells.
    Sato H; Siddig S; Uzu M; Suzuki S; Nomura Y; Kashiba T; Gushimiyagi K; Sekine Y; Uehara T; Arano Y; Yamaura K; Ueno K
    Eur J Pharmacol; 2015 Jan; 746():258-66. PubMed ID: 25455500
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lapatinib antagonizes multidrug resistance-associated protein 1-mediated multidrug resistance by inhibiting its transport function.
    Ma SL; Hu YP; Wang F; Huang ZC; Chen YF; Wang XK; Fu LW
    Mol Med; 2014 Sep; 20(1):390-9. PubMed ID: 25105301
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Selonsertib (GS-4997), an ASK1 inhibitor, antagonizes multidrug resistance in ABCB1- and ABCG2-overexpressing cancer cells.
    Ji N; Yang Y; Cai CY; Lei ZN; Wang JQ; Gupta P; Shukla S; Ambudkar SV; Kong D; Chen ZS
    Cancer Lett; 2019 Jan; 440-441():82-93. PubMed ID: 30315846
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ulixertinib (BVD-523) antagonizes ABCB1- and ABCG2-mediated chemotherapeutic drug resistance.
    Ji N; Yang Y; Lei ZN; Cai CY; Wang JQ; Gupta P; Xian X; Yang DH; Kong D; Chen ZS
    Biochem Pharmacol; 2018 Dec; 158():274-285. PubMed ID: 30431011
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Nilotinib potentiates anticancer drug sensitivity in murine ABCB1-, ABCG2-, and ABCC10-multidrug resistance xenograft models.
    Tiwari AK; Sodani K; Dai CL; Abuznait AH; Singh S; Xiao ZJ; Patel A; Talele TT; Fu L; Kaddoumi A; Gallo JM; Chen ZS
    Cancer Lett; 2013 Jan; 328(2):307-17. PubMed ID: 23063650
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dacomitinib antagonizes multidrug resistance (MDR) in cancer cells by inhibiting the efflux activity of ABCB1 and ABCG2 transporters.
    Fan YF; Zhang W; Zeng L; Lei ZN; Cai CY; Gupta P; Yang DH; Cui Q; Qin ZD; Chen ZS; Trombetta LD
    Cancer Lett; 2018 May; 421():186-198. PubMed ID: 29331420
    [TBL] [Abstract][Full Text] [Related]  

  • 32. BIRB796, the inhibitor of p38 mitogen-activated protein kinase, enhances the efficacy of chemotherapeutic agents in ABCB1 overexpression cells.
    He D; Zhao XQ; Chen XG; Fang Y; Singh S; Talele TT; Qiu HJ; Liang YJ; Wang XK; Zhang GQ; Chen ZS; Fu LW
    PLoS One; 2013; 8(1):e54181. PubMed ID: 23349819
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Crizotinib (PF-02341066) reverses multidrug resistance in cancer cells by inhibiting the function of P-glycoprotein.
    Zhou WJ; Zhang X; Cheng C; Wang F; Wang XK; Liang YJ; To KK; Zhou W; Huang HB; Fu LW
    Br J Pharmacol; 2012 Jul; 166(5):1669-83. PubMed ID: 22233293
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Icariin enhances cytotoxicity of doxorubicin in human multidrug-resistant osteosarcoma cells by inhibition of ABCB1 and down-regulation of the PI3K/Akt pathway.
    Wang Z; Yang L; Xia Y; Guo C; Kong L
    Biol Pharm Bull; 2015; 38(2):277-84. PubMed ID: 25747987
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tangeretin, a citrus pentamethoxyflavone, antagonizes ABCB1-mediated multidrug resistance by inhibiting its transport function.
    Feng SL; Yuan ZW; Yao XJ; Ma WZ; Liu L; Liu ZQ; Xie Y
    Pharmacol Res; 2016 Aug; 110():193-204. PubMed ID: 27058921
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CEP-33779 antagonizes ATP-binding cassette subfamily B member 1 mediated multidrug resistance by inhibiting its transport function.
    Tang SJ; Chen LK; Wang F; Zhang YK; Huang ZC; To KK; Wang XK; Talele TT; Chen ZS; Chen WQ; Fu LW
    Biochem Pharmacol; 2014 Sep; 91(2):144-56. PubMed ID: 25058526
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Overcoming ABCG2-mediated drug resistance with imidazo-[1,2-b]-pyridazine-based Pim1 kinase inhibitors.
    Darby RA; Unsworth A; Knapp S; Kerr ID; Callaghan R
    Cancer Chemother Pharmacol; 2015 Oct; 76(4):853-64. PubMed ID: 26351135
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Jadomycins are cytotoxic to ABCB1-, ABCC1-, and ABCG2-overexpressing MCF7 breast cancer cells.
    Issa ME; Hall SR; Dupuis SN; Graham CL; Jakeman DL; Goralski KB
    Anticancer Drugs; 2014 Mar; 25(3):255-69. PubMed ID: 24231527
    [TBL] [Abstract][Full Text] [Related]  

  • 39. P-glycoprotein Mediates Ceritinib Resistance in Anaplastic Lymphoma Kinase-rearranged Non-small Cell Lung Cancer.
    Katayama R; Sakashita T; Yanagitani N; Ninomiya H; Horiike A; Friboulet L; Gainor JF; Motoi N; Dobashi A; Sakata S; Tambo Y; Kitazono S; Sato S; Koike S; John Iafrate A; Mino-Kenudson M; Ishikawa Y; Shaw AT; Engelman JA; Takeuchi K; Nishio M; Fujita N
    EBioMedicine; 2016 Jan; 3():54-66. PubMed ID: 26870817
    [TBL] [Abstract][Full Text] [Related]  

  • 40. LRIG1, human EGFR inhibitor, reverses multidrug resistance through modulation of ABCB1 and ABCG2.
    Liu B; Guo Z; Dong H; Daofeng T; Cai Q; Ji B; Zhang S; Wu L; Wang J; Wang L; Zhu X; Liu Y; Chen Q
    Brain Res; 2015 Jun; 1611():93-100. PubMed ID: 25801120
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 103.